Daiichi Sankyo Co., Ltd., founded in 1899 and headquartered in Tokyo, Japan, is a global pharmaceutical company dedicated to innovative healthcare solutions. The company primarily focuses on the development and commercialization of new medicines in areas such as oncology, cardiovascular, and infectious diseases.
| Bond Name | Country | Maturity | Coupon(%) | |
|---|---|---|---|---|
| DAIICH 0.81% 2036-07-25 JPYDaiichi Sankyo Co., Ltd. | Japan | 2036-07-25 | 0.810 | 2.14 |
| DAIICH 1.20% 2046-07-25 JPYDaiichi Sankyo Co., Ltd. | Japan | 2046-07-25 | 1.200 | 3.18 |
Company overview and issue history are AI generated, and should not be cited or relied on without verification.
Daiichi Sankyo has been actively engaged in bond issuances since the early 2000s, with notable issuances including a 10-year bond in 2014 that raised ¥100 billion to finance R&D projects. As of October 2023, the company’s bonds yield around 0.7%, aligning closely with industry averages while positioning its creditworthiness favorably among peers. Recent news highlights a strategic initiative to refinance existing debt with a new issuance expected in early 2024, aiming to enhance liquidity and support ongoing growth initiatives.